KML'de in vivo T lenfosit fonksiyonlarının akım sitometrik değerlendirilmesi ve imatinib tedavisi sırasında ortaya çıkabilecek değişiklikler
No Thumbnail Available
Files
Date
2008
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Tıp Fakültesi
Abstract
Imatinib is a tyrosine kinase inhibitor being increasingly used today in the treatment of chronic myeloid leukemia. Imatinib is not only used in newly diagnosed CML patients but also used for patients in whom relaps occurred after allogeneic stem cell transplantation. Besides this, there are published articles reporting that imatinib has suppressive effects on T lymphocytes which primarily act on GVL effect. In this study, the effect of imatinib on T lymphocyte functions is evaluated in vivo by flow cytometry analysis. A total of 29 patients and 9 healthy control subjects were enrolled into the study. CML patients were divided into three groups as newly diagnosed patients having no treatment, patients using imatinib for 1 year and patients using imatinib for 2 years, respectively. To evaluate T lymphocyte functions, cells were induced by phorbol myristate acetate (PMA) and ionomisin, CD4+ T-cells were selected and IL-4 and IFN ? expression on these cells; how much percentage of CD3+ T cells were activated (CD3+CD69+); CD8+ T lymphocytes and the ratio and grade of expression of HLA-ABC and HLA-DR on those cells were evaluated, respectively. In our study, while CD8+ cell ratio was found to be statistically lower in all CML patient groups when compared to that of healthy control subjects (p=0.001); percent activity ratios were found to be significantly higher (p=0.002). No effect of imatinib on cytokine synthesis was observed. Further studies are needed to enlight whether there is correlation between in vivo and in vitro studies.
Description
Keywords
Hemetoloji